Centessa Pharmaceuticals
The Associate Director, Clinical Quality Assurance oversees GCP-focused quality assurance for Centessa-sponsored clinical trials, ensuring compliance with global regulations, ICH guidelines, and company SOPs. This role leads daily clinical quality operations, maintains effective quality programs, and ensures inspection readiness across all regulatory requirements. The position involves developing audit strategies, conducting site and vendor audits, and supporting regulatory inspections.
Centessa Pharmaceuticals is a global biopharmaceutical company that uses an asset‑centric, portfolio model to accelerate the development of innovative medicines. With a patient‑centric mission, Centessa advances programs across sleep‑wake, neurological, neurodegenerative and psychiatric disorders — notably pursuing an Orexin Receptor 2 agonist program. The company combines specialized operating subsidiaries and centralized capabilities to move preclinical and clinical‑stage assets efficiently toward regulatory approval and commercialization. Centessa partners with academic and industry collaborators to translate promising science into transformative treatment options for patients.
Why Centessa Pharmaceuticals (CNTA) Is Up 5.7% After Advancing ORX750 Toward Registrational Sleep-Disorder Trials
1 day ago
FMR LLC's Strategic Acquisition of Centessa Pharmaceuticals Shar
1 month ago
Centessa Pharmaceuticals plc Announces Underwritten Public Offering of American Depositary Shares
Nov 11, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Centessa Pharmaceuticals.
11% below the average for this role
Centessa (NASDAQ: CNTA) commences underwritten ADS offering; 30-day option up to 15%
Nov 11, 2025